Introduction
The BCR-ABL oncogenes comprise a family of fusion genes key to the genesis of a group of related myeloproliferative disorders. 1 These disorders include chronic myeloid leukemia (CML) and a proportion of cases that present as acute leukemia without evidence of a preceding chronic phase involving the myeloid lineages. The BCR-ABL oncogene associated with classical CML produces a 210 kDa oncoprotein (p210 BCR-ABL ) 2 that has a constitutively active tyrosine kinase encoded by the Src homology 1 (SH1) domain 3 and an abnormal cytoplasmic location. 4 Both of these features are key to the transforming activity of p210
BCR-ABL in model systems. [5] [6] [7] [8] [9] [10] The importance of the kinase function of p210 BCR-ABL in human BCR-ABL þ disease is indicated by the potent antileukemic effect of imatinib mesylate (Gleevec, STI571), [11] [12] [13] an agent that selectively blocks the kinase activity of p210 BCR-ABL . 9 Studies of the in vivo leukemogenic activity of primary mouse bone marrow (BM) cells transduced with P210
BCR-ABL constructs lacking the SH2 have yielded contradictory findings as to the importance of this domain. [14] [15] [16] In primary human hematopoietic cells, very little is known about the importance of different domains of p210 BCR-ABL with regard to its transforming activity. Primitive (CD34 þ ) cells from CML patients are characterized by factor-independent growth and differentiation in vitro. [17] [18] [19] [20] At the level of primitive CML progenitors, this abnormal behavior is due, at least in part, to the acquisition by the neoplastic cells of an autocrine interleukin-3 (IL-3)/granulocyte colony-stimulating factor (G-CSF) growth mechanism.
P210
BCR-ABL -induced production of IL-3 by hematopoietic cells was first demonstrated in various immortalized, factor-dependent cell lines, [22] [23] [24] and later confirmed in BCR-ABL-transduced primary mouse BM cells [25] [26] [27] and embryonic stem cells. 28 A subsequent study showed that the lethal leukemias obtained following the transplantation of large numbers of BCR-ABLtransduced IL3
À/À or granulocyte-macrophage colony-stimulating factor (GM-CSF) À/À mouse BM cells raised questions about the importance of autocrine factor production to the leukemogenic potential of primitive CML cells. 29 However, more recent experiments with the same model showed that the generation of leukemia was critically dependent on the persistence of an autocrine IL-3 mechanism when the production of other growth factors was attenuated by short-term passage of the BCR-ABLtransduced cells in culture prior to the transplantation of reduced numbers of leukemic stem cells. 27 We have also obtained evidence of an enhanced production of erythropoietin (Epo) transcripts in primary human CML progenitors (Jiang X, Fujisaki T, Berger M, Eaves A, Eaves C. Blood 1998; 92 (Suppl. 1): 254 (abstract)), which could contribute to the observed ability of some terminally differentiating CML erythroid precursors to mature in vitro in the absence of added Epo. 17 Forced expression of BCR-ABL in primary human hematopoietic cells offers a powerful strategy for creating new models of human CML to interrogate mechanisms of disease genesis and the effects of novel therapeutics. To date, the use of this approach has been limited, but perturbations in the adhesive properties of the transduced cells 30 and their lineage commitment 31 have been documented in transduced human cord blood (CB) cells. Here we show that these cells, like their murine counterparts, 27 rapidly acquire a growth factor-independent phenotype concomitant with the activation of IL-3, G-CSF and Epo expression. In addition, we show that inhibition of the SH1 (kinase) domain and deletion of the SH2 domain of p210 BCR-ABL have different effects on the BCR-ABL-induced perturbations of growth and differentiation exhibited by primitive human hematopoietic cells immediately post-transduction.
Materials and methods

Virus production
The MSCV-BCR-ABL-IRES-GFP vector (P210) encoding a fulllength b3a2 p210 BCR-ABL cDNA and the control MSCV-IRES-GFP (MIG) virus used here have both been described previously. 27 The MSCV-BCR-ABLDSH2-IRES-GFP vector (P210DSH2) containing a mutant (SH2-deleted) BCR-ABL cDNA (from R Van Etten, Center for Blood Research, Boston, MA, USA) was constructed by replacing the original BCR-ABL cDNA with the mutant cDNA in the same vector and was further verified by restriction enzyme digestion analysis (Figure 1) 
Retroviral transduction
Cells to be transduced were cultured at 1-2 Â 10 5 /ml for 48 h in Iscove's minimal essential Dulbecco's medium (IMDM, StemCell Technologies) supplemented with complete serum-free medium (SFM) containing the following five purified recombinant human growth factors: Flt-3 ligand (FL, 100 ng/ml, Immunex Corporation, Seattle, WA, USA), steel factor (SF, 100 ng/ml, produced in the Terry Fox Laboratory), IL-3 (20 ng/ ml, Novartis, Basel, Switzerland), IL-6 (20 ng/ml, Cangene, Mississauga, ON, Canada) and G-CSF (20 ng/ml, StemCell Technologies). The SFM consisted of IMDM supplemented with a combination of bovine serum albumin, insulin and transferrin (BITt, StemCell Technologies), 40 mg/ml low-density lipoproteins and 10 À4 mmol/l 2-mercaptoethanol (both from Sigma Chemicals, St Louis, MO, USA). The cells were then resuspended in filtered VCM supplemented with the same five growth factors and 5 mg/ml protamine sulfate (Sigma). The cells were then incubated at 371C for 12 h in fibronectin-coated Petri dishes previously 'loaded' twice with VCM (each time for 30 min). This infection procedure was repeated twice (three 12-h exposures to fresh virus) and the cells finally transferred to fresh SFM plus the same five growth factors but no VCM and incubated for a further 48 h prior to harvesting and further analysis. In experiments in which effects of imatinib mesylate (Gleevec/STI571, Novartis) were investigated, 0.25 mmol/l was added to the medium from the time of the first exposure to virus.
Flow cytometry
Viable GFP þ and GFP À CD34 þ CB cells were isolated at a purity of 499% using a three-laser FACStar þ cell sorter (Becton Dickinson, San Jose, CA, USA) and collected in eppendorf tubes containing complete SFM as described previously. 34 
Cultures
Transduced cells were cultured in IMDM with complete SFM with (or without) the same five growth factor cocktail used in the transduction protocol. Colony-forming cell (CFC) assays were performed in SFM-containing methylcellulose cultures (Methocult H4100, StemCell Technologies) supplemented or not with human SF (50 ng/ml) and 20 ng/ml each of human IL-3, IL-6, G-CSF and GM-CSF73 U/ml human Epo (StemCell Technologies) as described previously. 31 
Reverse transcriptase (RT)-PCR and Southern blot analyses
Total RNA was extracted from aliquots of 10 4 cells as described previously. 35 The RT reaction was performed in 20 ml volumes with superscript II RNase H À RT (GIBCO/BRL, Rockville, MD, USA) using random hexamer oligonucleotides as primers (Amersham Pharmacia). A measure of 5 ml of the RT reaction was then used for PCR amplification in 50 (5'-CCACACAGACAGCCACTCACCTCT-3' and 5'-CTGCAG-GAACTGGATCAGGACTTT-3') and GM-CSF (5'-CAGGAGGC CCGGCGTCTCCTGAAC-3' and 5'-ACAAGCAGAAAGTCCTT-CAGGTTC-3'). These generated DNA fragments of 374 bp (BCR-ABL), 493 bp (GAPDH), 345 bp (IL-3), 547 bp (G-CSF), 495 bp (TPO), 335 bp (SF), 289 bp (Epo), 341 bp (IL-6) and 300 bp (GM-CSF). A total of 35 cycles of amplification at 941C for 30 s, 621C for 1 min and 721C for 1 min were then performed. A measure of 10 ml aliquots of the PCR product were then electrophoresed, transferred to a nylon membrane and probed with cDNA probes for human IL-3, G-CSF, GM-CSF, IL-6, SF, Epo and GAPDH (from R Kay and K Humphries, Terry Fox Laboratory, Vancouver, BC, Canada), and for BCR-ABL (from J Griffin, Dana-Farber Cancer Center, Boston, MA, USA) as described previously. 21 For the detection of human TPO cDNA, an internal sequence (5 0 -CCGAGTCCTCAGTAAACTGCTTCG-3 0 ) was used as a hybridization probe.
Western analyses
A total of 10 5 cells per treatment group were lysed in phosphorylation solubilization buffer (PSB; 50 mmol/l Hepes buffer, 100 mmol/l NaF, 10 mmol/l sodium pyrophosphate, 2 mmol/l Na 3 VO 4 , 4 mmol/l EDTA) containing 0.5% Nonidet P-40, and Western analyses were performed as described previously using a mouse monoclonal anti-Abl antibody corresponding to the carboxyl region of Abl (Ab-3, Oncogene Research Products, Boston, MA, USA) and an antiphosphotyrosine antibody (4G10, Upstate Biotechnology, Lake Placid, NY, USA). 20 
Statistical analysis
Results are shown as the mean7s.e.m. of values obtained in at least three independent experiments. Differences between groups were assessed using the two-tailed Student's t-test.
Results
Rapid acquisition of growth autonomy by BCR-ABL-transduced human CB cells
In a first set of experiments, lin À CB cells (7273% CD34 þ ) were transduced with either the P210 or the control (MIG) vector ( Figure 1 ) after 2 days of growth factor prestimulation (with FL plus SF plus IL-3 plus IL-6 plus G-CSF) and then assessed for their ability to proliferate and differentiate in SFM in the presence or absence of added growth factors, both in suspension culture and in semisolid medium. The initial proportion of cells that were GFP þ (as assessed after 2 days in suspension cultures containing the same potent five growth factors used in the transduction protocol) was 1171% for P210 and 2874% for MIG (n ¼ 6). This result is consistent with the 2-to 3-fold higher titer of the MIG virus preparations as assessed on 3T3 cells. Interestingly, within the CD34 þ subset of CB cells, the % GFP þ cells 2 days post-transduction was the same for both vectors (772 and 871%), perhaps due to a selectively enhanced early rate of amplification of an initially lower fraction of P210-expressing CD34 þ cells. 31 The rapidity of the effect of p210 BCR-ABL on the growth rate of the transduced CB cells was seen also in the present experiments (Figure 2a) , where a 50-fold greater net expansion of the P210-transduced (sorted GFP þ ) cells vs MIG-transduced (sorted GFP þ ) cells over a 14-day period can be seen (100 000-fold vs 2000-fold, Po0.05, n ¼ 3).
Also shown in Figure 2a is a comparison of the changes in cell numbers seen in the parallel cultures initiated with the same sorted GFP þ cells to which no growth factors were added. Under these conditions, the P210-transduced CD34
þ cells expanded at a rate almost equivalent to that seen when the five growth factor cocktail was added (B2-fold less). In contrast, in the absence of growth factors, the control cells died rapidly. Similarly, when aliquots of the same transduced cells were plated immediately post-transduction in methylcellulose, many erythroid and granulocyte-macrophage or mixed colonies were obtained from the FACS-sorted P210-transduced (GFP þ ) cells in the absence of added growth factors (overall, at 17% the efficiency as with growth factors, Table 1 ). In contrast, the control cells formed colonies only in cultures to which growth factors were added. Comparison of the different types of colonies generated from the P210-and control-transduced cells showed a significant decrease in the number of granulopoietic colonies and a correspondingly increased number of erythroid colonies produced by the P210-transduced cells. We have previously shown that this lineage switching response is due to an ability of forced expression of P210 in uncommitted primary human progenitors to favor selection of the erythroid lineage, and a re-activation of erythroid potential and suppression of granulopoietic potential in progenitors otherwise thought to be already restricted to the granulocyte-macrophage pathway. 31 Rapid induction of expression of selected growth factors in P210-transduced human CD34
þ CB cells
To investigate the basis of the growth factor autonomy displayed by P210-transduced CD34 þ CB cells, we looked for evidence of activation of the same autocrine mechanisms operative in primary CD34
þ CML progenitors. These include the production of IL-3, G-CSF and Epo but not SF, TPO, GM-CSF or IL-6 21 (Jiang X, Fujisaki T, Berger M, Eaves A, Eaves C. Blood 1998; 92 (Suppl. 1): 254 (abstract)). Examination by RT-PCR of RNA extracts from FACS-sorted GFP þ cells transduced with either P210 or MIG and then cultured in suspension for 2, 3 and 7 days showed a rapid and selective induction of IL-3, G-CSF and Epo transcripts in the P210-transduced cells. Results representative of three similar experiments are shown in Figure 3 . In these experiments, both the P210-and MIG-transduced cells were cultured with growth factors to minimize selection of P210-transduced cells with the greatest factor independence and to minimize apoptosis in the control cultures. Transcripts for IL-3 and G-CSF were also consistently detectable in the MIGtransduced cells by day 7 of culture, presumably due to the generation by that time of mature cell types known to produce these growth factors (eg, mast cells and macrophages). When the same RNA extracts were analyzed for the presence of SF and IL-6 transcripts, only occasional and sporadic evidence of these was seen in both control-and P210-transduced cells (data not shown). A similar search for GM-CSF or TPO transcripts yielded totally negative results in all samples (data not shown).
Interference with the kinase activity of p210 BCR-ABL abrogates the growth factor independence of transduced human CB cells
We next asked whether the p210 BCR-ABL kinase activity was critical to the growth autonomy and autocrine factor production characteristic of P210-transduced CD34 þ CB cells. To address these questions, we cultured additional aliquots of cells of P210-transduced cells with or without growth factors in the presence of a low 'nontoxic' concentration (0.25 mmol/l) of imatinib mesylate that we had previously found to be sufficient to normalize the growth rate and differentiation of P210-transduced human CB cells cultured in the presence of growth factors. 31 This effect was confirmed in the present experiments (Figure 2b ). In contrast, in the absence of added growth factors, 0.25 mmol/l of imatinib mesylate caused a pronounced reduction in the growth of P210-transduced cells (10 4 times fewer viable cells present after 14 days, as indicated by a comparison CFC assays were performed 2 days after the completion of the transduction protocol to allow full expression of the transduced genes prior to plating in colony assays. Mean7s.e.m. values from three independent experiments are expressed per 100 pretransduction cells to allow the CFC expansion due to growth factor stimulation for 6 days to be normalized. GF ¼ growth factors. 
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of the data in Figure 2b with the data in Figure 2a for P210-transduced cells cultured without growth factors in the absence of the inhibitor). However, under these conditions, a complete restoration of the degree of factor dependence exhibited by control (MIG-transduced) cells was not achieved. To ascertain whether the marked effect of imatinib mesylate on the loss of factor independence by P210-transduced CB cells might be associated with a P210-kinase-dependent ability to activate autocrine growth factor production, transduced cells that had been cultured with 0.25 mmol/l imatinib mesylate (plus exogenously provided growth factors) were examined for the presence of growth factor transcripts. As shown in the right-hand lanes in Figure 3 , exposure to imatinib mesylate eliminated the early induction of IL-3 and Epo transcripts seen in control P210-transduced cells (cells cultured without the inhibitor shown on the left-hand side of Figure 3) , whereas the activation of G-CSF production, at least with this dose of inhibitor, appeared unaffected.
Deletion of the SH2 domain differentially affects the growth factor independence and altered commitment behavior of P210-transduced human CB cells
We then asked whether the SH2 domain of p210 BCR-ABL was also important to the acquisition by primitive human hematopoietic cells of a factor-independent phenotype. For this, we produced a retroviral vector capable of infecting human cells that was identical to the P210 vector but with the SH2 domain deleted (P210DSH2, Figure 1 ). The titer of the P210DSH2 virus as assessed on 3T3 cells was similar to that of the intact P210 virus, and lin À CB cells were also transduced with the P210DSH2 virus at a similar efficiency (1171% GFP þ total cells; 771% GFP þ CD34 þ cells, n ¼ 6) as described above for P210. However, the growth of P210DSH2-transduced CB cells in 14-day suspension cultures with growth factors was, unlike that exhibited by cells transduced with P210, not accelerated relative to the MIG-transduced controls (Figure 2a) . Furthermore, in the absence of added growth factors, the P210DSH2-transduced CB cells showed significantly diminished, albeit not completely abrogated, growth autonomy (100-fold less net expansion than the P210-transduced cells cultured without growth factors and 16-fold less net expansion than the P210DSH2-transduced cells cultured with growth factors, but still 41000-fold greater net expansion than the MIG-transduced cells cultured without growth factors, Po0.05).
A marked but incomplete restoration of factor dependence was also seen in the assays of the P210DSH2-transduced CB cells in semisolid medium (1.7% factor-independent colony formation vs 17% by P210, Table 1 ). However, this was not accompanied by more than a marginal change in the altered differentiation potential exhibited by the P210-transduced cells. Thus the significantly increased numbers of erythroid colonies and decreased numbers of granulocyte-macrophage colonies obtained from P210-transduced CB cells was also a feature of the assays of the P210DSH2-transduced CB cells, although there was evidence of a slightly diminished switch in the P210DSH2-transduced cells. This finding contrasts with the strongly normalizing effect on lineage commitment that we previously reported is obtained when P210-transduced human CB cells are assayed in the presence of 0.25 mmol imatinib mesylate. 31 Because previous studies have shown that deletion of the SH2 domain can reduce the kinase activity of P210 BCR-ABL in cell lines, 24, 36, 37 it was of interest to compare the levels of tyrosinephosphorylated proteins in primary P210-and P210DSH2-transduced human CB cells. Accordingly, FACS-sorted GFP þ
CD34
þ cells were cultured for 7 days in suspension culture with growth factors and then lysates prepared for Western analysis. As illustrated in Figure 4 , the level of expression of the mutant p210 BCR-ABLDSH2 in CB cells transduced with P210DSH2, as indicated by blotting with an anti-c-abl antibody, was consistently lower than the level of expression of intact p210 BCR-ABL in P210-transduced aliquots of the same target cells. However, both were still consistently much higher than the levels of P210 seen in K562 cells -an established human leukemic cell line with multiple Ph chromosomes. 38 This presumably reflects a greater potency of the long terminal repeat promoter of the vector in transduced cells by comparison to the BCR promoter in CML cells. Prior blotting of the same cell lysates with an antiphosphotyrosine antibody showed the levels of most of the tyrosine-phosphorylated proteins in the P210DSH2-expressing CB cells to be reduced relative to the P210-transduced CB cells, but higher than in K562 cells. However, some heterogeneity in the effect of the SH2 deletion on the reduction in phosphorylated proteins of different molecular weights was seen, as has been previously reported for other cell targets. 24, 36, 37 
Discussion
In this study, we have used a gene transfer strategy to demonstrate that the IL-3/G-CSF/Epo autocrine mechanism of growth autonomy characteristic of CD34 þ human CML cells . We also observed that transduction of primitive human CB cells with an SH2 domain-deficient BCR-ABL cDNA significantly compromised their ability to grow autonomously. Previous studies of the role of the SH2 domain in the induction of leukemogenic activity, growth factor autonomy and the activation of autocrine mechanisms by p210 BCR-ABL in either factor-dependent murine cell lines or primary murine hematopoietic cells have yielded contradictory results. In some cases, this domain was dispensible, 15, 16, 24, 36, 37, 39 but not in others. 14, 24, 40 One interpretation of these findings is that p210 BCR-ABL may confer growth factor autonomy by multiple mechanisms, of which autocrine growth factor production may be only one. Although this possibility was not specifically addressed in the present study, the incomplete restoration of normal growth factor dependence in the P210DSH2-transduced cells is consistent with such a hypothesis. Regardless of the final explanation, our present findings with the P210DSH2 mutant re-emphasize the importance of the cellular context in which the consequences of BCR-ABL expression are investigated, as confirmed for other downstream effects of p210 BCR-ABL . 26, 27, 41 As additionally demonstrated here, this includes the failure of P210
BCR-ABL to activate production of GM-CSF in primitive human hematopoietic cells in contrast to their murine counterparts. 25, 27 We also documented an enhanced production of Epo transcripts in naïve human progenitors forced to express p210 BCR-ABL and showed that this response was dependent on the kinase activity of this oncoprotein. The neoplastic erythroid progenitors from many CML patients display a sufficiently reduced requirement for Epo to allow the formation of recognizable colonies of hemoglobinized erythroblasts in vitro under conditions of Epo deprivation that do not support the growth and maturation of their normal counterparts, 17 in spite of the ability of the latter to produce low levels of Epo. 42, 43 The present experiments suggest the BCR-ABL-mediated activation of another autocrine loop in human hematopoietic targets with specificity for terminally differentiating erythroid cells. However, alternative mechanisms that do not involve Epo receptor activation may also be operative. 44 The rapidity of the activation of expression of IL-3, G-CSF and Epo in BCR-ABL-transduced human CD34
þ CB cells raises questions as to whether such an autocrine loop may play a role in the enhanced commitment to erythropoiesis that these cells exhibit immediately post-transduction. IL-3 45 and G-CSF 46 are well known for their ability to promote the expansion of primitive erythropoietic cells, as is the role of Epo as a critical regulator of the terminal stages of this pathway. 47 However, convincing evidences of cytokine-(or cytokine receptor-) directed changes in the erythroid commitment of pluripotent progenitors, or of cells already restricted to the granulocytemacrophage pathway, have not been reported. Indeed, most experimental strategies used to date to test such possibilities have yielded negative results. [48] [49] [50] Here we show that the autonomous growth potential acquired by BCR-ABL-transduced primary human hematopoietic cells, like their enhanced generation of erythroid progeny at the expense of granulopoietic cells, 31 is highly dependent on the kinase activity of the p210 BCR-ABL oncoprotein. In contrast, these two responses appear to be differentially affected by the removal of the SH2 domain from the P210 BCR-ABL cDNA used to transduce the cells. The SH2 deletion mutant significantly reduced their factor independence but had little impact on their perturbed commitment behavior. Taken together, these results indicate that qualitatively (or at least quantitatively) different mechanisms are required to mediate these changes and that the events that perturb the process of lineage restriction are unlikely to be downstream of a p210 BCR-ABL -activated autocrine mechanism. In summary, it appears that forced expression of high levels of p210 BCR-ABL in primitive normal human hematopoietic target cells can initiate a spectrum of biological changes that are differentially dependent on the integrity of different domains of this oncoprotein. The fact that some of these changes (eg, activation of the autocrine production of IL-3, G-CSF and Epo) are also characteristic of CML progenitors invites further exploitation of this model to analyze the precise sequence of molecular and biological events that lead to the genesis of this disease. On the other hand, the fact that other changes elicited by P210 in the relevant human target cells do not recapitulate features of human CML (eg, enhanced erythroid commitment) underscores the need for continuing improvement in the model, perhaps through a closer approximation of the levels of P210 BCR-ABL expression obtained in the more primitive types of CML cells taken directly from patients.
